C O M M U N I C A T I O N S
Table 2. Catalytic Enantioselective Conjugate Addition of Cyanide
to R,â-Unsaturated N-Acylpyrroles
Scheme 1. Conversion of the Products to Useful Compounds
pharmaceuticals and their lead compounds were achieved. Detailed
mechanistic studies and efforts to further improve the efficiency
are in progress.
Acknowledgment. Financial support was provided by Kuraray
Co. Ltd., PRESTO of Japan Science and Technology Agency (JST),
and Grant-in-Aid for Specially Promoted Research of MEXT. We
thank Ms. Sugita, Mr. Qin, and Dr. Matsunaga for helpful advice
regarding R,â-unsaturated N-acylpyrrole synthesis.
Supporting Information Available: Experimental procedures and
characterization of the products. This material is available free of charge
References
(1) (a) Sammis, G. M.; Jacobsen, E. N. J. Am. Chem. Soc. 2003, 125, 4442.
(b) Sammis, G. M.; Danjo, H.; Jacobsen, E. N. J. Am. Chem. Soc. 2004,
126, 9928.
(2) (a) Kato, N.; Suzuki, M.; Kanai, M.; Shibasaki, M. Tetrahedron Lett. 2004,
45, 3147. (b) Kato, N.; Suzuki, M.; Kanai, M.; Shibasaki, M. Tetrahedron
Lett. 2004, 45, 3153. (c) Masumoto, S.; Usuda, H.; Suzuki, M.; Kanai,
M.; Shibasaki, M. J. Am. Chem. Soc. 2003, 125, 5634.
(3) Kinetic studies and labeling experiments supported this reaction mechanism
in the catalytic enantioselective cyanosilylation of ketones using the
gadolinium complex: Yabu, K.; Masumoto, S.; Yamasaki, S.; Hamashima,
Y.; Kanai, M.; Du, W.; Curran, D. P.; Shibasaki, M. J. Am. Chem. Soc.
2001, 123, 9908.
(4) (a) Matsunaga, S.; Kinoshita, T.; Okada, S.; Harada, S.; Shibasaki, M. J.
Am. Chem. Soc. 2004, 126, 7559. (b) Evans, D. A.; Borg, G.; Scheidt, K.
A. Angew. Chem., Int. Ed. 2002, 41, 3188.
a Isolated yield. b Determined by chiral HPLC. c With 1 equiv of
TMSCN. d With 0.5 equiv of TMSCN. e The reaction experiment was
performed at room temperature. f Ratio of trans/cis. g Absolute configuration
was determined as shown in the above scheme. h Enantiomeric excess of
trans isomer. The absolute configuration was determined to be (2R,3R).
i Enantiomeric excess of cis isomer. The absolute configuration was
determined to be (2S,3R).
(5) Catalysts prepared from other lanthanide alkoxides produced less satisfac-
tory results.
(6) General Procedure: Gd(OiPr)3 (0.2 M in THF, 75 µL, 0.015 mmol) was
added to a solution of 2 (13.8 mg, 0.030 mmol) in THF (0.3 mL) at 0 °C.
The mixture was stirred at 45 °C for 1 h, and then the solvent was
evaporated at ambient temperature. After drying the resulting precatalyst
under reduced pressure (<5 mmHg) for 1.5 h, substrate 7f (53.1 mg, 0.30
mmol) in propionitrile (500 µL) was added at room temperature, then
cooled to -20 °C. After 20 min, TMSCN (20 µL, 0.15 mmol) was added,
and after 10 min, HCN (4 M in propionitrile stock solution, 150 µL, 0.60
mmol) was added to start the reaction.
(7) The cyanide addition proceeded with high enantioselectivity. Lack of the
diastereoselectivity is due to the nonstereoselective protonation of the
intermediate enolate.
(8) Sytinsky, I. A.; Soldatenkov, A. T. Prog. Neurobiol. 1978, 10, 89.
(9) For a procedure from the lactam to â-phenyl-substituted GABA analogue,
see: Sobocinska, M.; Zobacheva, M. M.; Perekalin, V. V.; Kupryszewski,
G. Pol. J. Chem. 1979, 53, 435.
in the nervous system, was synthesized in four steps from 8a
through hydrogenation of the cyanide and lactam formation.9
Second, pregabalin,10 an important anticonvulsant drug, was
synthesized in two steps from 8f. Third, trans-cyclopentanedicar-
boxylic acid, a useful chiral building block, was synthesized in two
steps from trans-8i.
In conclusion, we developed a catalytic enantioselective conju-
gate addition reaction of cyanide to R,â-unsaturated N-acylpyrroles
using the chiral gadolinium catalyst generated from Gd(OiPr)3 and
D-glucose-derived ligand 2. This reaction expands the previous
substrate scope significantly; substrates with â-aryl and â-vinyl
substituents and R,â-disubstituted substrates can now be used. Using
this reaction as a key step, short-step syntheses of several
(10) Pregabalin has a (3S) configuration: (a) Silverman, R. B.; Andruszkiewicz,
R.; Yuen, P.-W.; Sobieray, D. M.; Franklin, L. C.; Schwindt, M. A. U.S.
Patent 5,563,175, 1996. For recent catalytic enantioselective synthesis of
pregabalin, see: (b) Hoge, G. J. Am. Chem. Soc. 2003, 125, 10219, and
ref 1a. For a practical synthesis of (ent)-ligand 2, see: (c) Kato, N.; Tomita,
D.; Maki, K.; Kanai, M.; Shibasaki, M. J. Org. Chem. 2004, 69, 6128.
JA043424S
9
J. AM. CHEM. SOC. VOL. 127, NO. 2, 2005 515